Nocturnal urinary cortisol excretion over a randomized controlled trial with paroxetine vs. placebo combined with relaxation training or aerobic exercise in panic disorder

Current Pharmaceutical Design

Volumn 14, Issue 33, 2008, Pages 3518-3524

  Wedekind, D ^a   Sprute, A ^a   Broocks, A ^b   Huther G ^a   Engel, K ^a   Falkai, P ^a   Bandelow, B ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b HELIOS KLINIKEN SCHWERIN   (Germany)

Author keywords

Antidepressants; Cortisol; Gender; HPA axis; Panic disorder; Paroxetine

Indexed keywords

PAROXETINE; PLACEBO; HYDROCORTISONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AEROBIC EXERCISE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYDROCORTISONE RELEASE; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; PANIC; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAXATION TRAINING; REVIEW; SEX DIFFERENCE; ARTICLE; DRUG EFFECT; EXERCISE; HYPOPHYSIS ADRENAL SYSTEM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME; URINE;

ADULT; COMBINED MODALITY THERAPY; EXERCISE; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PANIC DISORDER; PAROXETINE; PITUITARY-ADRENAL SYSTEM; PLACEBOS; RELAXATION THERAPY; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 59849110181     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786848757     Document Type: Review

References (54)

1. Grammatopoulos DK, Chrousos GP. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab 2002; 13(10): 436-44.
2. Ising M, Kunzel HE, Binder EB, Nickel T, Modell S, Holsboer F. The combined dexamethasone/CRH test as a potentially surrogate marker in depression. Prog Neuropsychopharmacol 2005; 29: 1085-93.
3. Erhardt A, Ising M, Unschuld PG, Kern N, Lucae S, Putz B, et al. Regulation of the hypothalamic-pituitary-adrenocortical system in patients with panic disorder. Neuropsychopharmacology 2006; 31: 2515-22.
4. Uhde TW, Joffe RT, Jimerson DC, Post RM. Normal urinary free cortisol and plasma MHPG in panic disorder: Clinical and theoretical implications. Biol Psychiatry 1988; 23(6): 575-85.
5. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501.
6. De Kloet ER, Joels M, Holsboer F. Stress and the brain: From adaptation to desease. Nat Rev Neurosci 2005; 6: 463-75.
7. Lopez AL, Kathol RG, Noyes R. Reduction in urinary free cortisol during benzodiazepine treatment of panic disorder. Psychoneuroendocrinology 1990; 15(1): 23-8.
8. Zwanzger P, Eser D, Aicher S, Schule C, Baghai TC, Padberg F, et al. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: A placebo-controlled study. Neuropsychopharmacology 2003; 28(5): 979-84.
9. Schule C, Baghai T, Zwansger P, Rupprecht R. Attenuation of HPA axis hyperactivity and simultaneous deterioration in a depressed patient treated with mirtazapine. World J Biol Psychiatry 2001; 2: 103-5.
10. Schule C, Baghai T, Rackwitz C, Laakmann G. Influence of mirtazapine on urinary free cortisol excretion in depressed patients. Psychiatry Res 2003; 120; 257-64.
11. Schule C, Baghai TC, Eser D, Zwansger P, Jordan M, Buechs R, et al. Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients. Psychopharmacology (Berl) 2006; 186: 601-11.
12. De Boer TH. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995; 10 (Suppl 4): 19-23.
13. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, et al. Reduced serotonin type 1a receptor binding in panic disorder. J Neurosci 2004; 24: 589-91.
14. Gross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L, et al. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 2002; 416: 396-400.
15. Reul JM, Stec I, Soder M, Holsboer F. Chronic treatment of rats with the antidepressant amitrityline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 1993; 133(1): 312-20.
16. Reul JM, Stec I, Wiegers GJ, Labeur MS, Linthorst AC, Arzt E, et al. Prenatal immune challenge alters the hypothalamic-pituitary-adrenocortical axis in adult rats. J Cli Invest 1994; 93(6): 2600-7.
17. Barden N. Modulation of glucocorticoid receptor gene expression by antidepressant drugs. Pharmacopsychiatry 1996; 29: 12-22.
18. Barden N. Regulation of corticosteroid receptor gene expression in depression and antidepressant action. J Psychiatry Neurosci 1999; 24: 25-39.
19. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999; 160: 1-12.
20. Martins AP, Marras RA, Guimaraes FS. Anxiolytic effect of a CRH receptor antagonist in the dorsal periaqueductal gray. Depress Anxiety 2000; 12: 99-101.
21. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Therapeut 1999; 82(1): 1-61.
22. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 1999; 33: 181-214.
23. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological Treatment of anxiety, obsessive-compulsive disorder and posttraumatic stress disorder. World J Biol Psychiatry 2002; 3(4): 171-99.
24. Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJ Jr. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: Therapeutic implications. Brain Res 1992; 572: 117-25.
25. Keck ME, Welt T, Muller MB, Uhr M, Ohl F, Wigger A et al. Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioural and neuroendcrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology 2003; 28(2): 235-43.
26. Broocks A, Meyer T, Opitz M. 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. Eur Neuropsychopharmacol 2003; 13(3): 153-64.
27. Wedekind D, Bandelow B. Angststörungen. In: Rhode A, Marneros A Eds. Geschlechtsspezifische Psychiatrie und Psychotherapie: Stuttgart, Kohlhammer; 2007; 94-115.
28. Majewska MD. Neurosteroids: Endogenous bimodal modulqators of the GABA-A receptor. Mechanisms of action and physiological significance. Prog Neurobiol 1992; 38(4): 379-95.
29. Young EA, Altemus M, Lopez JF, Kocsis JH, Schatzberg AF, DeBattista C, et al. HPA axis activation in major depression and response to fluoxetine: A pilot study. Psychoneuroendocrinology 2004; 29 (9): 1198-1204.
30. Doering S, Wedekind D, Pilz J, Bandelow B, Adler L, Huether G. [Cortisol in night-urine: Introduction of a research method in psychoneuroendocrinology]. Z Psychosom Med Psychother 2001; 47: 42-57.
31. Anonymous. The declaration of Helsinki. World Med J 1982; 29(6): 86-8.
32. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Press; 1994.
33. WHO. World Health Organization. Tenth revision of the international classification of deseases, chapter V (F): Mental and behavioural disorders (including disorders of psychological development). Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1991.
34. Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia, II: The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 1995; 10: 73-81.
35. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md: US Department of Health, Education and Welfare 1976; 217-22.
36. Margraf J Diagnostisches Kurzinterview bei psychischen Störungen: Mini DIPS: Berlin, Springer; 1994.
37. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M SKID-I Strukturiertes Klinisches Interview fur DSM-IV, Achse I: Psychische Störungen: Hogrefe, Göttingen; 1997.
38. Hamilton M. Diagnosis and rating of anxiety. Br J Psychiatry (Special Publication) 1969; 3: 76-9.
39. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 1988; 56: 893-7.
40. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71.
41. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
42. Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 1998; 155(5): 603-9.
43. Gent S, Corbett K, Anyad AM, Wilson J, Artchisai A. comparison method of predicting maximum oxygen. Br J Sports Med 1995; 29(3): 147-52.
44. Schultz IH. Das autogene Training. Stuttgart, Germany: Thieme; 1932.
45. SAS Institute, Heidelberg: Germany; 2003.
46. Heuser IJ, Gotthard U, Schweiger U, Schmider J, Lammers CH, Dettling M, et al. Age-associated changes of the pituitary-adrenocortical hormone regulation in humans: Importance of gender. Neurobiol Aging 1994; 15: 227-31.
47. Kudielka BM, Kirschbaum C. Sex differences in the HPA axis responses to stress: A review. Biol Psychiatry 2005; 69: 113-32.
48. Künzel HE, Binder EB, Nickel T, Ising M, Fuchs B, Majer M, et al. Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test. Neuropsychopharmacology 2003; 28: 2169-78.
49. Pütz P. Hypercortisolemic disorders. In: Hellhammer DH, Hellhammer J Eds. Stress. The brain body connection. Key issues in mental health. Basel, Karger 2008; 174: 39-59.
50. Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 1996; 17: 187-205.
51. Raison CL, Miller AH. When not enough is too much: The role of insufficient glucocorticoid signalling in the pathophysiology of stress related disorders. Am J Psychiatry 2003; 160: 1554-65.
52. Annane D. Adrenal insufficiency in sepsis. Curr Pharm Des 2008; 14(19): 1882-6.
53. Gur A, Oktayoglu P. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: New concepts in treatment. Curr Pharm Des 2008; 14(13): 1274-94.
54. Sanna G, Bertolaccini ML, Khamashta MA. Neuropsychiatric involvement in systemic lupus erythematosus: Current therapeutic approach. Curr Pharm Des 2008; 14(13): 1261-9.